Los Angeles Capital Management LLC Takes $187,000 Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Los Angeles Capital Management LLC purchased a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 21,593 shares of the company’s stock, valued at approximately $187,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. 12 West Capital Management LP increased its holdings in Maravai LifeSciences by 92.2% in the 3rd quarter. 12 West Capital Management LP now owns 6,463,111 shares of the company’s stock valued at $64,631,000 after buying an additional 3,101,275 shares during the period. Point72 Europe London LLP acquired a new position in Maravai LifeSciences during the fourth quarter valued at approximately $17,059,000. Braidwell LP boosted its holdings in shares of Maravai LifeSciences by 120.3% in the 3rd quarter. Braidwell LP now owns 3,974,857 shares of the company’s stock valued at $39,749,000 after purchasing an additional 2,170,157 shares in the last quarter. Pacer Advisors Inc. increased its stake in shares of Maravai LifeSciences by 37.8% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,230 shares of the company’s stock valued at $19,357,000 after purchasing an additional 810,957 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Maravai LifeSciences by 80.5% during the 3rd quarter. AQR Capital Management LLC now owns 1,749,003 shares of the company’s stock worth $17,210,000 after buying an additional 779,838 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Robert W. Baird lifted their target price on Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, May 9th. Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They set a “buy” rating and a $15.00 price objective for the company. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.44.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the completion of the sale, the director now directly owns 20,150,005 shares in the company, valued at approximately $197,671,549.05. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.63% of the stock is owned by company insiders.

Maravai LifeSciences Price Performance

Shares of MRVI opened at $7.08 on Friday. The business has a 50-day moving average of $8.77 and a 200-day moving average of $7.56. Maravai LifeSciences Holdings, Inc. has a 1 year low of $4.52 and a 1 year high of $13.31. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -7.15 and a beta of 0.06. The company has a debt-to-equity ratio of 0.71, a current ratio of 11.32 and a quick ratio of 10.47.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The firm had revenue of $64.18 million during the quarter, compared to analyst estimates of $60.84 million. As a group, equities research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.